Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty... Read More